Shuttle Pharmaceuticals Holdings Inc SHPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 5.85M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.shuttlepharma.com
Valuation
|
Metric
|
SHPH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.75 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SHPH
|
|---|---|
Quick Ratio | 0.13 |
Current Ratio | 0.30 |
Interest Coverage | −151.39 |
Quick Ratio
SHPH
Profitability
|
Metric
|
SHPH
|
|---|---|
Return on Assets (Normalized) | −147.66% |
Return on Equity (Normalized) | −389.65% |
Return on Invested Capital (Normalized) | −319.67% |
Return on Assets
SHPH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Wxxlplyybj | Nrztlg | $69B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Hxqnyllrr | Ychwk | $40B | |||
| Haleon PLC ADR
HLN
| Wgqhrnznr | Bqfb | $39B | |||
| Zoetis Inc Class A
ZTS
| Llgdkwpcy | Zkfk | $33B | |||
| Viatris Inc
VTRS
| Rbwmjpds | Zwkn | $18B | |||
| Elanco Animal Health Inc
ELAN
| Kyhn | Dthv | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Gvswylx | Wdpn | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Pcycdmfzg | Tjmm | $6B | |||
| Curaleaf Holdings Inc
CURLD
| Xwqnbymz | Vjjl | $3B | |||
| Prestige Consumer Healthcare Inc
PBH
| Lthtvjyjx | Lybmgmc | $2B |
United States